Avectas’ technologies enable vector-free delivery of therapeutic agents to cells and tissues with application in ex vivo and in vivo gene-editing.
Empowering advances in new therapeutic strategies, Avectas' vector-free technology has demonstrated utility in gene editing. The Avectas technology demonstrates highly efficient and reproducible intracellular delivery by directing a fine spray dispersal of therapeutic agents (such as proteins, antibodies, siRNA, mRNA, and DNA) to cells including immune and stem cells, ex-vivo and to tissues in-vivo.
Avectas' gene editing approach can be summed up as 'transient tools for enduring effects'. Viruses and other vectors have been associated with significant safety concerns and other limitations. Avectas' unique patented technologies achieve comparable delivery efficiency and viability without vector related complications.